Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Enterprise Value (2016 - 2025)

Ligand Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$139.4 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 119.08% year-over-year to -$139.4 million; the TTM value through Dec 2025 reached -$1.1 billion, down 313.41%, while the annual FY2024 figure was -$256.2 million, 1015.99% down from the prior year.
  • Enterprise Value for Q3 2025 was -$139.4 million at Ligand Pharmaceuticals, up from -$245.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$5.3 million in Q2 2022 and bottomed at -$341.1 million in Q4 2021.
  • The 5-year median for Enterprise Value is -$63.6 million (2024), against an average of -$127.0 million.
  • The largest annual shift saw Enterprise Value soared 95.58% in 2022 before it crashed 1785.31% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$341.1 million in 2021, then surged by 37.89% to -$211.9 million in 2022, then soared by 89.17% to -$23.0 million in 2023, then plummeted by 1015.99% to -$256.2 million in 2024, then skyrocketed by 45.59% to -$139.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Enterprise Value are -$139.4 million (Q3 2025), -$245.0 million (Q2 2025), and -$208.9 million (Q1 2025).